Online inquiry

IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15236MR)

This product GTTS-WQ15236MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15236MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15398MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ11462MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ7948MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ13872MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ10629MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ3076MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ3073MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ7563MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC33
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW